Multiple myeloma: The present and the future

Medical Journal of Australia

Volumn 183, Issue 7, 2005, Pages 344-

  Joshua, Douglas E ^a  

^a ROYAL PRINCE ALFRED HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; BORTEZOMIB; DEXAMETHASONE; LENALIDOMIDE; MELPHALAN; PARAPROTEIN; THALIDOMIDE;

ALLOGENEIC STEM CELL TRANSPLANTATION; ANEMIA; AUTOLOGOUS STEM CELL TRANSPLANTATION; BACKACHE; BONE LESION; BONE MARROW TOXICITY; BONE NECROSIS; CANCER CHEMOTHERAPY; CLINICAL FEATURE; CLINICAL TRIAL; EDITORIAL; ENVIRONMENTAL EXPOSURE; HUMAN; HYPERCALCEMIA; JAW DISEASE; KIDNEY FAILURE; LIFESTYLE; MOLECULAR BIOLOGY; MONOCLONAL IMMUNOGLOBULINEMIA; MULTIPLE MYELOMA; NEUROPATHY; PATHOGENESIS; RISK FACTOR; TREATMENT PLANNING;

EID: 26444468948     PISSN: 0025729X     EISSN: None     Source Type: Journal    
DOI: 10.5694/j.1326-5377.2005.tb07079.x     Document Type: Editorial

References (10)

1. Baris D, Lan Q, Zhang Y, et al. Epidemiology of multiple myeloma [abstract]. Haematologica 2005; 90 Suppl 1: 11.
2. Kyle RA, Therneau TM, Rajkumar SV, et al. Long-term follow up of 241 patients with monoclonal gammopathy of undetermined significance: the original Mayo Clinic series 25 years later. Mayo Clin Proc 2004; 79: 859-866.
3. Attal M, Harousseau JL, Stoppa AM, et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome. N Engl J Med 1996; 335: 91-97.
4. Attal M, Harousseau JL, Facon T, et al; InterGroupe Francophone du Myelome. Single versus double autologous stem-cell transplantation for multiple myeloma. N Engl J Med 2003; 349: 2495-2502.
5. Roodman GD. Mechanisms of bone metastasis. N Engl J Med 2004; 350: 1655-1664.
6. Berenson JR, Rosen LS, Howell A, et al. Zoledronic acid reduces skeletal-related events in patients with osteolytic metastases. Cancer 2001; 91: 1191-1200.
7. Singhal S, Mehta J, Desikan R, et al. Antitumour activity of thalidomide in refractory multiple myeloma. N Engl J Med 1999; 341: 1565-1571.
8. Richardson PG, Schlossman RL, Weller E, et al. Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma. Blood 2002; 100: 3063-3067.
9. Richardson PG. Bortezomib - first in the class of proteasome inhibitors and an important advance in the treatment of multiple myeloma [abstract]. Haematologica 2005; 90 Suppl 1: 23-24.
10. Attal M, Harousseau JL, Leyvraz S, et al. Maintenance treatment with thalidomide and pamidronate after autologous transplantation for myeloma: second analysis of a prospective randomized study of the Intergroupe Francophone du Myelome [abstract]. Haematologica 2005; 90 Suppl 1: 17.